{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T15:01:08Z","timestamp":1783004468746,"version":"3.54.5"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T00:00:00Z","timestamp":1595894400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T00:00:00Z","timestamp":1595894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["91439207"],"award-info":[{"award-number":["91439207"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s10557-020-07041-6","type":"journal-article","created":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T07:38:12Z","timestamp":1595921892000},"page":"141-151","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["PCSK9Q\u03b2-003 Vaccine Attenuates Atherosclerosis in Apolipoprotein E-Deficient Mice"],"prefix":"10.1007","volume":"35","author":[{"given":"Danyu","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajie","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanzhao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingxuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihua","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhua","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihua","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,28]]},"reference":[{"key":"7041_CR1","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJM199901143400207","volume":"340","author":"R Ross","year":"1999","unstructured":"Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999;340:115\u201326.","journal-title":"N Engl J Med"},{"key":"7041_CR2","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1161\/CIRCRESAHA.115.306301","volume":"118","author":"MA Gimbrone Jr","year":"2016","unstructured":"Gimbrone MA Jr, Garc\u00eda-Carde\u00f1a G. Endothelial cell dysfunction and the pathobiology of atherosclerosis. Circ Res. 2016;118:620\u201336.","journal-title":"Circ Res"},{"key":"7041_CR3","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1126\/science.3513311","volume":"232","author":"MS Brown","year":"1986","unstructured":"Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science. 1986;232:34\u201347.","journal-title":"Science"},{"key":"7041_CR4","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1172\/JCI116663","volume":"92","author":"S Ishibashi","year":"1993","unstructured":"Ishibashi S, Brown MS, Goldstein JL, Gerard RD, Hammer RE, Herz J. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest. 1993;92:883\u201393.","journal-title":"J Clin Invest"},{"key":"7041_CR5","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","volume":"34","author":"M Abifadel","year":"2003","unstructured":"Abifadel M, Varret M, Rab\u00e8s JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34:154.","journal-title":"Nat Genet"},{"key":"7041_CR6","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/humu.20882","volume":"30","author":"M Abifadel","year":"2009","unstructured":"Abifadel M, Rab\u00e8s JP, Devillers M, et al. Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease. Hum Mutat. 2009;30:520\u20139.","journal-title":"Hum Mutat"},{"key":"7041_CR7","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.bbalip.2008.01.003","volume":"1781","author":"D Lopez","year":"2008","unstructured":"Lopez D. PCSK9: an enigmatic protease. Biochim Biophys Acta. 2008;1781:184\u201391.","journal-title":"Biochim Biophys Acta"},{"key":"7041_CR8","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1086\/507488","volume":"79","author":"Z Zhao","year":"2006","unstructured":"Zhao Z, Tuakli WY, Lagace TA, et al. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet. 2006;79:514\u201323.","journal-title":"Am J Hum Genet"},{"key":"7041_CR9","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","volume":"385","author":"FJ Raal","year":"2015","unstructured":"Raal FJ, Stein EA, Dufour R, et al. RUTHERFORD-2 investigators. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385:331\u201340.","journal-title":"Lancet"},{"key":"7041_CR10","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s10557-016-6685-y","volume":"30","author":"HN Ginsberg","year":"2016","unstructured":"Ginsberg HN, Rader DJ, Raal FJ, et al. Efficacy and safety of Alirocumab in patients with heterozygous familial hypercholesterolemia and LDL-C of 160 mg\/dl or higher. Cardiovasc Drugs Ther. 2016;30:473\u201383.","journal-title":"Cardiovasc Drugs Ther"},{"key":"7041_CR11","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jama.2016.11004","volume":"316","author":"DS Kazi","year":"2016","unstructured":"Kazi DS, Moran AE, Coxson PG, et al. Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease. JAMA. 2016;316:743\u201353.","journal-title":"JAMA"},{"key":"7041_CR12","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrd1284","volume":"3","author":"MF Bachmann","year":"2004","unstructured":"Bachmann MF, Dyer MR. Therapeutic vaccination for chronic diseases: a new class of drugs in sight. Nat Rev Drug Discov. 2004;3:81.","journal-title":"Nat Rev Drug Discov"},{"key":"7041_CR13","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/MOL.0000000000000312","volume":"27","author":"B Chackerian","year":"2016","unstructured":"Chackerian B, Remaley A. Vaccine strategies for lowering LDL by immunization against proprotein convertase subtilisin\/kexin type 9. Curr Opin Lipidol. 2016;27:345\u201350.","journal-title":"Curr Opin Lipidol"},{"key":"7041_CR14","doi-asserted-by":"crossref","first-page":"12534","DOI":"10.1038\/s41598-017-13069-w","volume":"7","author":"Y Pan","year":"2017","unstructured":"Pan Y, Zhou Y, Wu H, et al. Therapeutic peptide vaccine against PCSK9. Sci Rep. 2017;7:12534.","journal-title":"Sci Rep"},{"key":"7041_CR15","first-page":"293","volume":"209","author":"A Daugherty","year":"2003","unstructured":"Daugherty A, Whitman SC. Quantification of atherosclerosis in mice. Methods Mol Biol. 2003;209:293\u2013309.","journal-title":"Methods Mol Biol"},{"key":"7041_CR16","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S0092-8674(01)00238-0","volume":"104","author":"CK Glass","year":"2001","unstructured":"Glass CK, Witztum JL. Atherosclerosis: the road ahead. Cell. 2001;104:503\u201316.","journal-title":"Cell"},{"key":"7041_CR17","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1080\/07853890310008198","volume":"35","author":"S Vainio","year":"2003","unstructured":"Vainio S, Ikonen E. Macrophage cholesterol transport: a critical player in foam cell formation. Ann Med. 2003;35:146\u201355.","journal-title":"Ann Med"},{"key":"7041_CR18","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.atherosclerosis.2015.06.042","volume":"242","author":"SD Lee","year":"2015","unstructured":"Lee SD, Tontonoz P. Liver X receptors at the intersection of lipid metabolism and atherogenesis. Atherosclerosis. 2015;242:29\u201336.","journal-title":"Atherosclerosis"},{"key":"7041_CR19","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00005-012-0179-9","volume":"60","author":"GM Pascual","year":"2012","unstructured":"Pascual GM, Valledor AF. Biological roles of liver X receptors in immune cells. Arch Immunol Ther Exp. 2012;60:235\u201349.","journal-title":"Arch Immunol Ther Exp"},{"key":"7041_CR20","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.plipres.2010.03.002","volume":"49","author":"MH Oosterveer","year":"2010","unstructured":"Oosterveer MH, Grefhorst A, Groen AK, Kuipers F. The liver X receptor: control of cellular lipid homeostasis and beyond implications for drug design. Prog Lipid Res. 2010;49:343\u201352.","journal-title":"Prog Lipid Res"},{"key":"7041_CR21","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2174\/1874192401610010233","volume":"10","author":"V Kolovou","year":"2016","unstructured":"Kolovou V, Marvaki A, Boutsikou M, et al. Effect of ATP-binding cassette transporter A1 (ABCA1) gene polymorphisms on plasma lipid variables and common demographic parameters in Greek nurses. Open Cardiovasc Med J. 2016;10:233\u20139.","journal-title":"Open Cardiovasc Med J"},{"key":"7041_CR22","doi-asserted-by":"crossref","first-page":"28240","DOI":"10.1074\/jbc.M003337200","volume":"275","author":"P Costet","year":"2000","unstructured":"Costet P, Luo Y, Wang N, Tall AR. Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor\/retinoid X receptor. J Biol Chem. 2000;275:28240\u20135.","journal-title":"J Biol Chem"},{"key":"7041_CR23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2016.11.019","volume":"256","author":"MP Adorni","year":"2017","unstructured":"Adorni MP, Cipollari E, Favari E, Zanotti I, et al. Inhibitory effect of PCSK9 on Abca1 protein expression and cholesterol efflux in macrophages. Atherosclerosis. 2017;256:1\u20136.","journal-title":"Atherosclerosis"},{"issue":"3","key":"7041_CR24","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.1365-2796.2007.01898.x","volume":"263","author":"AR Tall","year":"2008","unstructured":"Tall AR. Cholesterol efflux pathways and other potential mechanisms involved in the athero-protective effect of high density lipoproteins. J Intern Med. 2008;263(3):256\u201373.","journal-title":"J Intern Med"},{"key":"7041_CR25","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","volume":"372","author":"MS Sabatine","year":"2015","unstructured":"Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1500\u20139.","journal-title":"N Engl J Med"},{"key":"7041_CR26","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1194\/jlr.C600025-JLR200","volume":"48","author":"MJ Graham","year":"2007","unstructured":"Graham MJ, Lemonidis KM, Whipple CP, et al. Antisense inhibition of proprotein convertase subtilisin\/kexin type 9 reduces serum LDL in hyperlipidemic mice. J Lipid Res. 2007;48:763\u20137.","journal-title":"J Lipid Res"},{"key":"7041_CR27","doi-asserted-by":"crossref","first-page":"9820","DOI":"10.1073\/pnas.0903849106","volume":"106","author":"JC Chan","year":"2009","unstructured":"Chan JC, Piper DE, Cao Q, et al. A proprotein convertase subtilisin\/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc Natl Acad Sci U S A. 2009;106:9820\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"7041_CR28","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/nm1459","volume":"12","author":"MC Clarke","year":"2006","unstructured":"Clarke MC, Figg N, Maguire JJ, et al. Apoptosis of vascular smooth muscle cells induces features of plaque vulnerability in atherosclerosis. Nat Med. 2006;12:1075\u201380.","journal-title":"Nat Med"},{"issue":"9","key":"7041_CR29","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1161\/hc0902.104353","volume":"105","author":"P Libby","year":"2002","unstructured":"Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105(9):1135\u201343.","journal-title":"Circulation"},{"key":"7041_CR30","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s00441-013-1699-2","volume":"354","author":"P May","year":"2013","unstructured":"May P, Bock HH, Nofer JR. Low density receptor-related protein 1 (LRP1) promotes anti-inflammatory phenotype in murine macrophages. Cell Tissue Res. 2013;354:887\u20139.","journal-title":"Cell Tissue Res"},{"key":"7041_CR31","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1194\/jlr.M053207","volume":"55","author":"B Ason","year":"2014","unstructured":"Ason B, Van der Hoorn JWA, Chan J, et al. PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE. J Lipid Res. 2014;55:2370\u20139.","journal-title":"J Lipid Res"},{"key":"7041_CR32","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.atherosclerosis.2013.01.023","volume":"227","author":"E Levy","year":"2013","unstructured":"Levy E, Ben Djoudi Ouadda A, Spahis S, et al. PCSK9 plays a significant role in cholesterol homeostasis and lipid transport in intestinal epithelial cells. Atherosclerosis. 2013;227:297\u2013306.","journal-title":"Atherosclerosis"},{"key":"7041_CR33","doi-asserted-by":"crossref","first-page":"19266","DOI":"10.1074\/jbc.M112.363382","volume":"287","author":"V Sharotri","year":"2012","unstructured":"Sharotri V, Collier DM, Olson DR, Zhou R, Snyder PM. Regulation of epithelial sodium channel trafficking by proprotein convertase subtilisin\/kexin type 9 (PCSK9). J Biol Chem. 2012;287:19266\u201374.","journal-title":"J Biol Chem"},{"key":"7041_CR34","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1161\/ATVBAHA.108.181586","volume":"29","author":"MC Le","year":"2009","unstructured":"Le MC, Kourimate S, Langhi C, et al. Proprotein convertase subtilisin kexin type 9 null mice are protected from postprandial triglyceridemia. Arterioscler Thromb Vasc Biol. 2009;29:684\u201390.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"7041_CR35","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1074\/jbc.M708098200","volume":"283","author":"S Poirier","year":"2008","unstructured":"Poirier S, Mayer G, Benjannet S, et al. The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. J Biol Chem. 2008;283:2363\u201372.","journal-title":"J Biol Chem"},{"key":"7041_CR36","doi-asserted-by":"crossref","first-page":"e0191895","DOI":"10.1371\/journal.pone.0191895","volume":"13","author":"R Kawakami","year":"2018","unstructured":"Kawakami R, Nozato Y, Nakagami H, et al. Development of vaccine for dyslipidemia targeted to a proprotein convertase subtilisin\/kexin type 9 (PCSK9) epitope in mice. PLoS One. 2018;13:e0191895.","journal-title":"PLoS One"},{"key":"7041_CR37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-37186-2","volume":"9","author":"S Schuster","year":"2019","unstructured":"Schuster S, Rubil S, Endres M, et al. Anti-PCSK9 antibodies inhibit pro-atherogenic mechanisms in APOE*3Leiden.CETP mice. Sci Rep. 2019;9:1\u20138.","journal-title":"Sci Rep"},{"issue":"12","key":"7041_CR38","doi-asserted-by":"crossref","first-page":"e114469","DOI":"10.1371\/journal.pone.0114469","volume":"9","author":"G Galabova","year":"2014","unstructured":"Galabova G, Brunner S, Winsauer G, et al. Peptide-based anti-PCSK9 vaccines- an approach for long-term LDLc management. PLoS One. 2014;9(12):e114469.","journal-title":"PLoS One"},{"key":"7041_CR39","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1093\/eurheartj\/ehx260","volume":"38","author":"C Landlinger","year":"2017","unstructured":"Landlinger C, Pouwer MG, Juno C, et al. The AT04A vaccine against proprotein convertase subtilisin\/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice. Eur Heart. 2017;38:2499\u2013507.","journal-title":"Eur Heart"},{"key":"7041_CR40","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s12916-019-1457-8","volume":"17","author":"AA Momtazi-Borojeni","year":"2019","unstructured":"Momtazi-Borojeni AA, Jaafari MR, Badiee A, Banach M, Sahebkar A. Therapeutic effect of nanoliposomal PCSK9 vaccine in a mouse model of atherosclerosis. BMC Med. 2019;17:223.","journal-title":"BMC Med"},{"key":"7041_CR41","doi-asserted-by":"crossref","first-page":"e014358","DOI":"10.1161\/JAHA.119.014358","volume":"9","author":"D Wu","year":"2020","unstructured":"Wu D, Zhou Y, Pan Y, et al. Vaccine against PCSK9 improved renal fibrosis by regulating fatty acid \u03b2-oxidation. J Am Heart Assoc. 2020;9:e014358.","journal-title":"J Am Heart Assoc"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-020-07041-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-020-07041-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-020-07041-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T20:32:47Z","timestamp":1667593967000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-020-07041-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,28]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["7041"],"URL":"https:\/\/doi.org\/10.1007\/s10557-020-07041-6","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,28]]},"assertion":[{"value":"17 July 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All applicable international, national, and\/or institutional guidelines for the care and use of animals were followed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}